QuidelOrtho logo

QuidelOrtho

QDEL | NASDAQ
Chart Builder DCF Calculator
$10.21
-$0.53 (-4.93%)
At close: Nov 16, 2026, 4:00 PM ET
$10.19
-$0.02 (-0.20%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.93%

Rating

Updated: Nov 16, 2026
41.4
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #484/1021 (Top 47%)

Key Statistics

Market Data

Market Cap $700.53M
1D Range
10.18 11.06
52W Range
9.96 35.38

Valuation (TTM)

PE -1.88
PB 0.39
EV/EBITDA 1.98

Valuation (NTM)

Forward PE 16.03
Forward PEG 0.03
Price Target $12.25
Loading financial charts...

Profile

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct busines...

Sector Healthcare
Employees 6,500
IPO Date Feb 1, 1991
Fiscal Year January - December

Latest News

Faster Answers, Better Decisions: ADLM 2026 Highlights

3 months ago · prnewswire.com

Faster Answers, Better Decisions: ADLM 2026 Highlights
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho Q2 Earnings Call Highlights

3 months ago · marketbeat.com

QuidelOrtho Q2 Earnings Call Highlights
QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates

3 months ago · zacks.com

QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
QuidelOrtho Reports Second Quarter 2026 Financial Results

3 months ago · prnewswire.com

QuidelOrtho Reports Second Quarter 2026 Financial Results
Implied Volatility Surging for QuidelOrtho Stock Options

3 months ago · zacks.com

Implied Volatility Surging for QuidelOrtho Stock Options
QuidelOrtho to Report Second Quarter 2026 Financial Results

4 months ago · prnewswire.com

QuidelOrtho to Report Second Quarter 2026 Financial Results
Reasons to Add QuidelOrtho Stock in Your Portfolio for Now

4 months ago · zacks.com

Reasons to Add QuidelOrtho Stock in Your Portfolio for Now
Beyond Fentanyl: How the Drug Crisis Is Changing

4 months ago · prnewswire.com

Beyond Fentanyl: How the Drug Crisis Is Changing
Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm

4 months ago · businesswire.com

Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm

Earnings

Latest Earnings
Nov 3, 2026
EPS
$0.31
Beat +53.62%
REV
$618.9M
Miss -1.42%
Next Earnings
Feb 10, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Hold
Price Target
$12.25
Upside
+19.98%
Buy (0)
Hold (3)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.